Ngo Son Tung, Nguyen Hung Minh, Thuy Huong Le Thi, Quan Pham Minh, Truong Vi Khanh, Tung Nguyen Thanh, Vu Van V
Laboratory of Theoretical and Computational Biophysics, Ton Duc Thang University Ho Chi Minh City 700000 Vietnam
Faculty of Applied Sciences, Ton Duc Thang University Ho Chi Minh City 700000 Vietnam.
RSC Adv. 2020 Nov 9;10(66):40284-40290. doi: 10.1039/d0ra07352k. eCollection 2020 Nov 2.
The main protease (Mpro) of the novel coronavirus SARS-CoV-2, which has caused the COVID-19 pandemic, is responsible for the maturation of its key proteins. Thus, inhibiting SARS-CoV-2 Mpro could prevent SARS-CoV-2 from multiplying. Because new inhibitors require thorough validation, repurposing current drugs could help reduce the validation process. Many recent studies used molecular docking to screen large databases for potential inhibitors of SARS-CoV-2 Mpro. However, molecular docking does not consider molecular dynamics and thus can be prone to error. In this work, we developed a protocol using free energy perturbation (FEP) to assess the potential inhibitors of SARS-CoV-2 Mpro. First, we validated both molecular docking and FEP on a set of 11 inhibitors of SARS-CoV-2 Mpro with experimentally determined inhibitory data. The experimentally deduced binding free energy exhibits significantly stronger correlation with that predicted by FEP ( = 0.94 ± 0.04) than with that predicted by molecular docking ( = 0.82 ± 0.08). This result clearly shows that FEP is the most accurate method available to predict the binding affinity of SARS-CoV-2 Mpro + ligand complexes. We subsequently used FEP to validate the top 33 compounds screened with molecular docking from the ZINC15 database. Thirteen of these compounds were predicted to bind strongly to SARS-CoV-2 Mpro, most of which are currently used as drugs for various diseases in humans. Notably, delamanid, an anti-tuberculosis drug, was predicted to inhibit SARS-CoV-2 Mpro in the nanomolar range. Because both COVID-19 and tuberculosis are lung diseases, delamanid has higher probability to be suitable for treating COVID-19 than other predicted compounds. Analysis of the complexes of SARS-CoV-2 Mpro and the top inhibitors revealed the key residues involved in the binding, including the catalytic dyad His14 and Cys145, which is consistent with the structural studies reported recently.
引发新冠疫情的新型冠状病毒SARS-CoV-2的主要蛋白酶(Mpro)负责其关键蛋白的成熟。因此,抑制SARS-CoV-2 Mpro可阻止SARS-CoV-2繁殖。由于新抑制剂需要全面验证,重新利用现有药物有助于缩短验证过程。最近许多研究使用分子对接在大型数据库中筛选SARS-CoV-2 Mpro的潜在抑制剂。然而,分子对接未考虑分子动力学,因此可能容易出错。在这项工作中,我们开发了一种使用自由能微扰(FEP)来评估SARS-CoV-2 Mpro潜在抑制剂的方案。首先,我们在一组具有实验测定抑制数据的11种SARS-CoV-2 Mpro抑制剂上验证了分子对接和FEP。实验推导的结合自由能与FEP预测值( = 0.94 ± 0.04)的相关性显著强于与分子对接预测值( = 0.82 ± 0.08)的相关性。这一结果清楚地表明,FEP是预测SARS-CoV-2 Mpro + 配体复合物结合亲和力的最准确方法。我们随后使用FEP验证了从ZINC15数据库中通过分子对接筛选出的前33种化合物。这些化合物中有13种预计会与SARS-CoV-2 Mpro紧密结合,其中大多数目前被用作治疗人类各种疾病的药物。值得注意的是,抗结核药物地拉曼德预计在纳摩尔范围内抑制SARS-CoV-2 Mpro。由于新冠和结核病都是肺部疾病,与其他预测化合物相比,地拉曼德更有可能适合治疗新冠。对SARS-CoV-2 Mpro与顶级抑制剂复合物的分析揭示了结合过程中涉及的关键残基,包括催化二元组His14和Cys145,这与最近报道的结构研究结果一致。